Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Colorectal cancer is a prevalent global malignancy.
• Cyclooxygenase-2 (COX-2) suppression is under investigation for cancer chemoprevention.
• Aspirin, NSAIDs, and selective COX-2 inhibitors are drugs that can inhibit COX-2.

Purpose of the Study:

• To evaluate the effectiveness and safety of COX-2 suppression for colorectal cancer chemoprevention.
• To determine optimal drug choices, duration of use, and potential side effects for chemoprevention strategies.
• To analyze the risk-benefit ratio of using these medications for long-term chemoprevention.

Main Methods:

• Review of observational studies and randomized controlled trials.
• Analysis of evidence regarding the efficacy of aspirin and related drugs in cancer prevention.
• Assessment of reported side effects, specifically gastrointestinal bleeding risks.

Main Results:

• Long-term, low-dose aspirin use demonstrates encouraging benefits in preventing proximal colon cancers and adenomas.
• Evidence suggests aspirin is particularly effective for preventing cancers and adenomas in the proximal colon.
• Increased risk of gastrointestinal bleeding is a significant concern with long-term aspirin and related drug use.

Conclusions:

• Aspirin, particularly at low doses, shows potential for colorectal cancer chemoprevention, especially for proximal tumors.
• The long-term use of aspirin and similar drugs necessitates a thorough evaluation of the associated gastrointestinal bleeding risks.
• Careful consideration of the risk-benefit profile is crucial when implementing chemoprevention strategies involving these medications.